ClinicalTrials.gg
RecruitingNCT06889701Updated Oct 19, 2026

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

A Phase 1/2 interventional study of TNP-2092 for injection and Vancomycin Hydrochloride for Injection (IA) in Periprosthetic Joint Infection (PJI), sponsored by TenNor Therapeutics Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by TenNor Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 19, 2026Study documents postedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered via IA injection on the basis of vancomycin IV and oral antibiotics therapy in participants with early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requiring or not requiring DAIR therapy after TKA, or requiring long-term antibiotic suppression therapy for PJI (including PJI occurring after various joint replacements and revision surgeries).

Read the detailed description

The study population is participants with confirmed or suspected Gram-positive bacteria causing early (ie, within 1 month of TKA) or acute hematogenous (within 3 weeks of infection symptoms) PJI requiring or not requiring DAIR therapy following TKA, or requiring long-term antibiotic suppression therapy for PJI (including PJI occurring after various joint replacement and revision surgeries). Participants will undergo screening assessments within 7 days prior to study start.

02

Conditions studied

  • Periprosthetic Joint Infection (PJI)
03

In context

Lead sponsor

TenNor Therapeutics Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requires or does not require DAIR therapy after TKA, or results of treatment for PJI (including PJI occurring after various joint replacements and revision surgeries) did not meet the clinical cure criteria and requiring long-term antibiotic suppression therapy as judged by investigators before enrollment.
  • Suspected or confirmed PJI was caused by a Gram-positive bacterial infection, including methicillin-resistant and ciprofloxacin-resistant Staphylococcus aureus and Staphylococcus epidermidis, as judged by the investigator.
  • Agree to be hospitalized for 2 weeks with local intra-articular injection.
  • 18 years of age or older (of either sex) at the time of signing the form (ICF).
  • The implanted prosthetic joint was well fixed.
  • No sinus tract that communicates with the prosthesis.
  • (BMI) ≥ 18 kg/m\^2 and ≤ 34 kg/m\^2.
  • Agree to voluntarily use effective from signing the ICF through 8 weeks after the last dose of product (in case of premature withdrawal from the study) or through completion of the end-of-study visit. Male participants must refrain from donating sperm during this period.

Exclusion criteria

Exclusion Criteria:

  • History of or intolerance to any of the following agents: vancomycin or TNP-2092.
  • Definite PJI of Gram-negative infection, fungal infection, or Enterococcus infection, or Mycobacterium infection, or Gram-positive mixed Gram-negative and/or fungal infection.
  • Definite systemic infection (sepsis).
  • Expected survival less than 1 years.
  • Female participant is pregnant, lactating, or has a positive screening/baseline pregnancy test.
  • Surgical or medical conditions that, in the opinion of the investigator, could affect the participant's ability to participate in the study, or affect the administration of product, or affect the interpretation of study results, including but not limited to active , metabolic disease, alcohol or drug abuse, or laboratory abnormalities.
  • Presence of serious liver, blood, or immune system disorders as evidenced by the following:

    1. Acute hepatitis of any cause within the past year.
    2. Serum (ALT), aspartate aminotransferase (AST), or total levels > 2 times the (ULN).
    3. Presence of end-stage liver disease-related manifestations such as ascites or hepatic encephalopathy.
    4. Current or anticipated neutropenia (ie, \< 0.5 x 10\^9/L).
    5. Chemotherapy for cancer, radiation therapy, or potent noncorticosteroid (eg, cyclosporine, azathioprine, tacrolimus, immunomodulatory monoclonal antibody therapy, etc) within the past 3 months or (≥ 40 mg prednisone/day) for more than 14 days within 30 days prior to randomization.
  • Positive AIDS antibody screening.
  • History or evidence of severe renal disease or \< 30 mL/min based on the Cockcroft-Gault formula.
  • Treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • Participants who, in the opinion of the investigator, were unable to comply with the protocol and study drug administration procedures or complete the clinical study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Sentinel group

    In the sentinel group, participants will receive TNP-2092 50 mg IA+vancomycin IV+oral antibiotics.

    Drug: TNP-2092 for injection · Drug: Vancomycin Hydrochloride for Injection (IV) · Drug: Oral antibiotics

  • Experimental
    Experimental group

    In the experimental group, participants will receive TNP-2092 50 mg IA + vancomycin IV + oral antibiotics.

    Drug: TNP-2092 for injection · Drug: Vancomycin Hydrochloride for Injection (IV) · Drug: Oral antibiotics

  • Active comparator
    Control group

    In the control group, participants will receive vancomycin IA + vancomycin IV + oral antibiotics.

    Drug: Vancomycin Hydrochloride for Injection (IA) · Drug: Vancomycin Hydrochloride for Injection (IV) · Drug: Oral antibiotics

  • Experimental
    Expansion group

    In the expansion group, participants will receive TNP-2092 50 mg IA based on the background treatment.

    Drug: TNP-2092 for injection · Drug: Background Treatment

Interventions

  • TNP-2092 for injection, 100 mg/vial, Intra-articular administration (IA), 10ml (50 mg) once daily for 14 days. TNP-2092 dose volume, dose, frequency, and duration can be adjusted according to the sentinel group synovial fluid TNP-2092 concentration, PK characteristics, and safety results at the EA visit.

    Also known as: rifaquizinone for injection

  • Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intra-articular administration, 10 mL (0.5 g) once daily for 14 days.

  • Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intravenous infusion, 250 mL (1 g) q12h ± 1h per day, for 14 days.

  • DrugOral antibiotics

    Rifampicin capsules: 0.15 g/capsule. 0.45 g (3 capsules) orally once daily within 1 h before breakfast for 8 weeks (56 days). Levofloxacin Tablets: 0.5 g/tablet. 0.5 g (1 tablet) orally once daily within 1 hour before breakfast for 8 weeks (56 days). If susceptibility testing results show resistance to rifampicin and/or levofloxacin, or intolerance by the patient 's participant, treatment with oral minocycline hydrochloride capsules will be substituted as follows:Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time for 8 weeks (56 days). The total duration of oral treatment during the oral administration period was 8 weeks (56 days) regardless of whether oral medication will be changed (eg, intolerance).

  • DrugBackground Treatment

    Background treatment will be determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of TNP-2092 by Assessment of the Number of Adverse Events (AEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Day 1 to Day 187

Secondary outcomes

  1. TNP-2092 concentrations in synovial fluid

    Synovial fluid concentrations of TNP-2092 were measured by a specific and validated assay.

    Time frame: At 12, 24 hours after the first dose of TNP-2092, before dosing on Day 7, before the last dose, and at 12, 24, 48 hours after the last dose.

  2. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 after the first dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the first dose

  3. Time to Reach the Maximum Observed Plasma Concentration (Tmax) after the first dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the first dose

  4. Area under the curve from the time of dosing to the last measurable concentration (AUC 0-t) after the first dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the first dose

  5. Area under the curve from the time of dosing to infinity (AUC 0-∞) after the first dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the first dose

  6. Elimination half-life (t 1/2) after the first dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the first dose

  7. Maximum observed concentration at steady state (Cmax, ss) after the last dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24, 48 hours after the last dose

  8. Time to maximum concentration at steady state (Tmax, ss) after the last dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24, 48 hours after the last dose

  9. Area under the curve from the time of dosing to the last measurable concentration at steady state (AUC 0-t, ss) after the last dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24, 48 hours after the last dose

  10. Area under the curve from the time of dosing to infinity at steady state (AUC 0-∞, ss) after the last dose

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24, 48 hours after the last dose

  11. Area under the curve over the dosing interval at steady state (AUC 0-tau, ss)

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24 hours after the last dose

  12. Elimination half-life at steady state (t 1/2, ss)

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour), 1, 4, 12, 24, 48 hours after the last dose

  13. Accumulation ratio (Rac)

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Before administration (within 1 hour) of the first dose, 1, 4, 12, 24 hours after the first dose; Before administration (within 1 hour) of the last dose, 1, 4, 12, 24 hours after the last dose

  14. Early Assessment (EA) response rate

    Participants with early or acute hematogenous PJI after TKA who met all the following criteria will be judged as responders: * At least 2 body temperature measurements within the last 24 hours separated by more than 6 hours were ≤ 37.6ºC. * Peripheral white blood cell (WBC) count returned to normal range (as determined by local laboratory reference range). * Synovial fluid WBC \< 3000 cell/μL and polymorphonuclear leukocytes percentage (PMN%) \< 80%. * Inflammatory manifestations (pain, erythema, edema, wound exudate) at the primary infection site resolved, with pain requiring resolution or tolerance. * Inflammatory markers (ie, C-reactive protein \[CRP\]) improved to 50% of normal or baseline values.

    Time frame: Day 14

  15. End of treatment (EOT) response rate

    Participants who met all the following criteria were judged as responders: * Joint pain resolved or tolerated. * Joint function improvement. * Inflammatory markers (ie, CRP) returned to ≤ 10 mg/L.

    Time frame: Day 71 to Day 77

  16. Treatment failure rate

    Those who meet any of the following criteria are treatment failures: * No response at EA assessment (only for participants with early or acute hematogenous PJI after TKA). * No response at EOT assessment. * Receiving systemic antibiotics for infected joints after the end of study treatment. * Additional surgical treatment of infected joints is required during the study. * Death due to primary joint infection.

    Time frame: Within 6 months and 12 months after the start of study treatment, respectively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Jan 2027 and completion Aug 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 21, 2025
StartActual
Apr 3, 2025
Primary completionEst.
Jan 2027was Aug 2026
CompletionEst.
Jan 2027was Aug 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Jan 2027
Oct 13, 2026
Study completion
Aug 2026→Jan 2027
Oct 13, 2026
Documents
Oct 19, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameTreatment failure rateWithin 6 months after the start of study treatment → Within 6 months and 12 months after the start of study treatment, respectively
Oct 19, 2026
Show all 2 updates
  1. Oct 19, 2026
    Documents Study protocol ↗ updated
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameTreatment failure rateWithin 6 months after the start of study treatment → Within 6 months and 12 months after the start of study treatment, respectively
  2. Oct 13, 2026
    Primary completion Aug 2026→Jan 2027
    Study completion Aug 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06889701
Lead sponsor
TenNor Therapeutics Inc.
Collaborators
First Affiliated Hospital of Xinjiang Medical University
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Apr 3, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Li Cao
Contact
xjbone@sina.com
+86 991-4366553
Jing Chen
Contact
jing.chen@tennorx.com
+86 512 86861979

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TNP-2092 · Vancomycin

Start the discussion